<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043366</url>
  </required_header>
  <id_info>
    <org_study_id>GWang001</org_study_id>
    <nct_id>NCT02043366</nct_id>
  </id_info>
  <brief_title>Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients</brief_title>
  <official_title>Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Postoperative Hyperalgesia Induced by Remifentanil in Patients Undergoing Lower Abdomimal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:

      To explore and compare antihyperalgesic effects of butorphanol, flurbiprofen axetil, and a
      combination of both received before anesthesia induction.

      To evaluate and examine the incidence of adverse effects with the purpose of selecting the
      optimum dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are a dramatically increasing number of evidences that administration of the potent,
      ultra-short-acting opioid remifentanil seems to cause opioid-induced hyperalgesia (OIH) more
      frequently and predictably compared with the others, likely due to its rapid onset and
      offset. Therefore, prophylaxis of remifentanil induced hyperalgesia is indispensable to
      postoperative comfort and satisfaction.

      There is no denying the fact that OIH is related to central glutaminergic system and
      N-methyl-d-aspartate (NMDA) receptor-activation induced central sensitization. Prostaglandins
      can promote glutamate release from both astrocytes and spinal cord dorsal horns with
      subsequent activation of the NMDA receptors, and flurbiprofen axetil, as non-steroidal
      anti-inflammatory drugs (NSAIDs), not only functionally antagonizes the NMDA receptor
      activation via inhibition of prostaglandins, but also is a targeted drug which gathers at the
      site of inflammation, thus greatly enhances the analgesic effect. While butorphanol has both
      spinal analgesic and sedative functions because of predominantly central κ-receptor agonist
      activation, other advantages of butorphanol include few side effects, very low addiction
      potential, and low toxicity on account of a partial agonist-antagonist activity to
      μ-receptor. Moreover, antihyperalgesic activity of κ opioids at the site of inflammation has
      been reported in various acute pain models. The following study is carried out to evaluate
      whether butorphanol combined with flurbiprofen axetil can be safely and effectively applied
      to preventing postoperative hyperalgesia induced by remifentanil in patients undergoing lower
      abdominal surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>The mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament at 24 hours postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score (NRS)</measure>
    <time_frame>3h, 6h, 12h, and 24h after surgery</time_frame>
    <description>The pain score at rest was evaluated by pain 11-point numerical rating scale (NRS): 0 = no pain, 10 = greatest imaginable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of First Postoperative Analgesic Requirement</measure>
    <time_frame>1 hour post surgery</time_frame>
    <description>First postoperative pain (NRS≥5) is initially controlled by titration of sufentanyl.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Side Effects</measure>
    <time_frame>24 hours</time_frame>
    <description>Occurrence of side effects: nausea, vomiting, dizziness, headache, shivering, pruritus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Dose of First Postoperative Analgesic Requirement</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>First postoperative pain (NRS≥5) is initially controlled by titration of sufentanyl.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Sufentanyl Consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Each patient was administered analgesics using a PCA pump containing sufentanil (100μg) in normal saline at a total volume of 100 ml after leaving PACU. This device was set to deliver a basal infusion of 2 ml/h and bolus doses of 0.5 ml with a 15-min lockout period. Sufentanyl cumulative consumption is recorded 24 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized Area of Hyperalgesia Around the Incision</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>The skin around the incision is stimulated in steps of 5 mm at intervals of 1 s starting outside of the hyperalgesic area in the direction of the incision. The distance from the incision to the first point where a 'painful', 'sore' or 'sharper' feeling occurred is measured and noted. This measurement is repeated at predefined radial lines around the incision. To eliminate the variable length of incision, this length is subtracted from the longer diameter leaving four radial distances from the end and from the middle of the incision. The normalized area of hyperalgesia is calculated by summing up the areas of the remaining four triangles measured by and Von Frey filament.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Pain</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Butorphanol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Butorphanol is intravenously administrated at a dose of 20μg/ kg before anesthesia induction and intraoperative pain management was with remifentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flurbiprofen axetilⅠ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before anesthesia induction and intraoperative pain management was with remifentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flurbiprofen axetilⅡ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before the skin closure and intraoperative pain management was with remifentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Butorphanol-Flurbiprofen axetil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A dose of 10μg/ kg butorphanol and a dose of 0.5mg/ kg flurbiprofen axetil are intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sufentanil</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with sufentanil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Normal Saline is intravenously administrated before anesthesia induction</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_label>Sufentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butorphanol</intervention_name>
    <description>Butorphanol is intravenously administrated</description>
    <arm_group_label>Butorphanol</arm_group_label>
    <arm_group_label>Butorphanol-Flurbiprofen axetil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flurbiprofen axetil</intervention_name>
    <description>Flurbiprofen axetil is intravenously administrated</description>
    <arm_group_label>Flurbiprofen axetilⅠ</arm_group_label>
    <arm_group_label>Flurbiprofen axetilⅡ</arm_group_label>
    <arm_group_label>Butorphanol-Flurbiprofen axetil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil is intravenously administrated</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_label>Butorphanol</arm_group_label>
    <arm_group_label>Flurbiprofen axetilⅠ</arm_group_label>
    <arm_group_label>Flurbiprofen axetilⅡ</arm_group_label>
    <arm_group_label>Butorphanol-Flurbiprofen axetil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>Sufentanil is intravenously administrated</description>
    <arm_group_label>Sufentanil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is scheduled to undergo lower abdominal surgery under a short general
             anesthesia of less than 2 hours

          2. Subject's American Society of Anesthesiologists physical status is I-II.

          3. The subject's parent/legally authorized guardian has given written informed consent to
             participate.

        Exclusion Criteria:

          1. Subject has a diagnosis of renal or liver failure.

          2. Subject has a diagnosis of Insulin dependent diabetes.

          3. Subject is allergy and contraindication to butorphanol or NSAIDs.

          4. Subject has a history of chronic pain, a history of alcohol or opioid abuse,
             pre-existing therapy with opioids, intake of any analgesic drug within 48 hours before
             surgery.

          5. Subject has any contraindication for the use of patient-controlled analgesia (PCA).

          6. Subject is pregnant or breast-feeding.

          7. Subject is obese (body mass index &gt;30kg/m^2).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guolin Wang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tianjin Medical University General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <results_first_submitted>August 27, 2015</results_first_submitted>
  <results_first_submitted_qc>August 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 28, 2015</results_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Medical University General Hospital</investigator_affiliation>
    <investigator_full_name>Guolin Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Remifentanil</keyword>
  <keyword>Opioid-induced hyperalgesia</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Pain Intensity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Butorphanol</mesh_term>
    <mesh_term>Flurbiprofen</mesh_term>
    <mesh_term>Flurbiprofen axetil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From February 2014 to June 2015, patients were recruited and estimated for eligibility</recruitment_details>
      <pre_assignment_details>Exclusion criteria: coronary heart disease, bronchial asthma, cardiac, lung, hepatic and renal insufficiency, severe hypertension, diabetes mellitus, psychiatric disease, obesity, a history of chronic pain, a history of alcohol or opioid abuse, pregnancy, allergy and contraindication to study drugs, a history of gastrointestinal disease</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Normal Saline</title>
          <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
Normal Saline</description>
        </group>
        <group group_id="P2">
          <title>Flurbiprofen AxetilⅠ</title>
          <description>Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
Flurbiprofen axetil: Flurbiprofen axetil is intravenously administrated</description>
        </group>
        <group group_id="P3">
          <title>Flurbiprofen AxetilⅡ</title>
          <description>Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before the skin closure and intraoperative pain management was with remifentanil
Flurbiprofen axetil: Flurbiprofen axetil is intravenously administrated</description>
        </group>
        <group group_id="P4">
          <title>Butorphanol</title>
          <description>Butorphanol is intravenously administrated at a dose of 20μg/ kg before anesthesia induction and intraoperative pain management was with remifentanil.</description>
        </group>
        <group group_id="P5">
          <title>Butorphanol-Flurbiprofen Axetil</title>
          <description>A dose of 10μg/kg butorphanol and a dose of 0.5mg/kg flurbiprofen axetil are intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil.</description>
        </group>
        <group group_id="P6">
          <title>Sufentanil</title>
          <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with sufentanil.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal Saline</title>
          <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
Normal Saline</description>
        </group>
        <group group_id="B2">
          <title>Flurbiprofen AxetilⅠ</title>
          <description>Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
Flurbiprofen axetil: Flurbiprofen axetil is intravenously administrated</description>
        </group>
        <group group_id="B3">
          <title>Flurbiprofen AxetilⅡ</title>
          <description>Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before the skin closure and intraoperative pain management was with remifentanil
Flurbiprofen axetil: Flurbiprofen axetil is intravenously administrated</description>
        </group>
        <group group_id="B4">
          <title>Butorphanol</title>
          <description>Butorphanol is intravenously administrated at a dose of 20μg/ kg before anesthesia induction and intraoperative pain management was with remifentanil.</description>
        </group>
        <group group_id="B5">
          <title>Butorphanol-Flurbiprofen Axetil</title>
          <description>A dose of 10μg/ kg butorphanol and a dose of 0.5mg/ kg flurbiprofen axetil are intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil.</description>
        </group>
        <group group_id="B6">
          <title>Sufentanil</title>
          <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with sufentanil.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="28"/>
            <count group_id="B5" value="28"/>
            <count group_id="B6" value="28"/>
            <count group_id="B7" value="168"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.2" spread="11.0"/>
                    <measurement group_id="B2" value="45.3" spread="9.7"/>
                    <measurement group_id="B3" value="47.9" spread="10.0"/>
                    <measurement group_id="B4" value="46.5" spread="9.7"/>
                    <measurement group_id="B5" value="45.1" spread="7.9"/>
                    <measurement group_id="B6" value="43.5" spread="10.8"/>
                    <measurement group_id="B7" value="45.5" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm</title>
        <description>The mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament at 24 hours postoperatively</description>
        <time_frame>24 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline</title>
            <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
Normal Saline</description>
          </group>
          <group group_id="O2">
            <title>Flurbiprofen AxetilⅠ</title>
            <description>Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
Flurbiprofen axetil: Flurbiprofen axetil is intravenously administrated</description>
          </group>
          <group group_id="O3">
            <title>Flurbiprofen AxetilⅡ</title>
            <description>Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before the skin closure and intraoperative pain management was with remifentanil
Flurbiprofen axetil: Flurbiprofen axetil is intravenously administrated</description>
          </group>
          <group group_id="O4">
            <title>Butorphanol</title>
            <description>Butorphanol is intravenously administrated at a dose of 20μg/ kg before anesthesia induction and intraoperative pain management was with remifentanil.</description>
          </group>
          <group group_id="O5">
            <title>Butorphanol-Flurbiprofen Axetil</title>
            <description>A dose of 10μg/ kg butorphanol and a dose of 0.5mg/ kg flurbiprofen axetil are intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil.</description>
          </group>
          <group group_id="O6">
            <title>Sufentanil</title>
            <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with sufentanil</description>
          </group>
        </group_list>
        <measure>
          <title>Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm</title>
          <description>The mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament at 24 hours postoperatively</description>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.57" spread="22.55"/>
                    <measurement group_id="O2" value="78.29" spread="24.76"/>
                    <measurement group_id="O3" value="68.50" spread="21.98"/>
                    <measurement group_id="O4" value="79.7" spread="20.93"/>
                    <measurement group_id="O5" value="81.64" spread="20.40"/>
                    <measurement group_id="O6" value="89.5" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score (NRS)</title>
        <description>The pain score at rest was evaluated by pain 11-point numerical rating scale (NRS): 0 = no pain, 10 = greatest imaginable pain.</description>
        <time_frame>3h, 6h, 12h, and 24h after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of First Postoperative Analgesic Requirement</title>
        <description>First postoperative pain (NRS≥5) is initially controlled by titration of sufentanyl.</description>
        <time_frame>1 hour post surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Side Effects</title>
        <description>Occurrence of side effects: nausea, vomiting, dizziness, headache, shivering, pruritus</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Dose of First Postoperative Analgesic Requirement</title>
        <description>First postoperative pain (NRS≥5) is initially controlled by titration of sufentanyl.</description>
        <time_frame>1 hour after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Sufentanyl Consumption</title>
        <description>Each patient was administered analgesics using a PCA pump containing sufentanil (100μg) in normal saline at a total volume of 100 ml after leaving PACU. This device was set to deliver a basal infusion of 2 ml/h and bolus doses of 0.5 ml with a 15-min lockout period. Sufentanyl cumulative consumption is recorded 24 hours postoperatively</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normalized Area of Hyperalgesia Around the Incision</title>
        <description>The skin around the incision is stimulated in steps of 5 mm at intervals of 1 s starting outside of the hyperalgesic area in the direction of the incision. The distance from the incision to the first point where a ‘painful’, ‘sore’ or ‘sharper’ feeling occurred is measured and noted. This measurement is repeated at predefined radial lines around the incision. To eliminate the variable length of incision, this length is subtracted from the longer diameter leaving four radial distances from the end and from the middle of the incision. The normalized area of hyperalgesia is calculated by summing up the areas of the remaining four triangles measured by and Von Frey filament.</description>
        <time_frame>24 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline</title>
            <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
Normal Saline</description>
          </group>
          <group group_id="O2">
            <title>Flurbiprofen AxetilⅠ</title>
            <description>Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
Flurbiprofen axetil: Flurbiprofen axetil is intravenously administrated</description>
          </group>
          <group group_id="O3">
            <title>Flurbiprofen AxetilⅡ</title>
            <description>Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before the skin closure and intraoperative pain management was with remifentanil
Flurbiprofen axetil: Flurbiprofen axetil is intravenously administrated</description>
          </group>
          <group group_id="O4">
            <title>Butorphanol</title>
            <description>Butorphanol is intravenously administrated at a dose of 20μg/ kg before anesthesia induction and intraoperative pain management was with remifentanil</description>
          </group>
          <group group_id="O5">
            <title>Butorphanol-Flurbiprofen Axetil</title>
            <description>A dose of 10μg/ kg butorphanol and a dose of 0.5mg/ kg flurbiprofen axetil are intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil</description>
          </group>
          <group group_id="O6">
            <title>Sufentanil</title>
            <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with sufentanil</description>
          </group>
        </group_list>
        <measure>
          <title>Normalized Area of Hyperalgesia Around the Incision</title>
          <description>The skin around the incision is stimulated in steps of 5 mm at intervals of 1 s starting outside of the hyperalgesic area in the direction of the incision. The distance from the incision to the first point where a ‘painful’, ‘sore’ or ‘sharper’ feeling occurred is measured and noted. This measurement is repeated at predefined radial lines around the incision. To eliminate the variable length of incision, this length is subtracted from the longer diameter leaving four radial distances from the end and from the middle of the incision. The normalized area of hyperalgesia is calculated by summing up the areas of the remaining four triangles measured by and Von Frey filament.</description>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.46" spread="9.98"/>
                    <measurement group_id="O2" value="53.64" spread="8.63"/>
                    <measurement group_id="O3" value="56.57" spread="8.98"/>
                    <measurement group_id="O4" value="54.00" spread="9.30"/>
                    <measurement group_id="O5" value="52.5" spread="9.15"/>
                    <measurement group_id="O6" value="49.89" spread="8.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Incidence of adverse effects was evaluated during 24h after surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Normal Saline</title>
          <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
Normal Saline</description>
        </group>
        <group group_id="E2">
          <title>Flurbiprofen AxetilⅠ</title>
          <description>Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
Flurbiprofen axetil: Flurbiprofen axetil is intravenously administrated</description>
        </group>
        <group group_id="E3">
          <title>Flurbiprofen AxetilⅡ</title>
          <description>Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before the skin closure and intraoperative pain management was with remifentanil
Flurbiprofen axetil: Flurbiprofen axetil is intravenously administrated</description>
        </group>
        <group group_id="E4">
          <title>Butorphanol</title>
          <description>Butorphanol is intravenously administrated at a dose of 20μg/ kg before anesthesia induction and intraoperative pain management was with remifentani</description>
        </group>
        <group group_id="E5">
          <title>Butorphanol-Flurbiprofen Axetil</title>
          <description>A dose of 10μg/ kg butorphanol and a dose of 0.5mg/ kg flurbiprofen axetil are intravenously administrated before anesthesia induction and intraoperative pain management was with remifentani</description>
        </group>
        <group group_id="E6">
          <title>Sufentanil</title>
          <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with sufentanil</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Guolin Wang</name_or_title>
      <organization>Tianjin Medical University General Hospital</organization>
      <phone>+8615822855556</phone>
      <email>wangguolinghad@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

